New study tests hormone combo to boost IVF success in adenomyosis patients

NCT ID NCT06239376

Recruiting now Disease control Sponsor: Mỹ Đức Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study tests whether a two-month hormone pretreatment (GnRH agonist plus letrozole) before standard frozen embryo transfer can improve live birth rates in women with adenomyosis. About 222 participants will be randomly assigned to either the new regimen or standard care. The goal is to find a more effective way to prepare the uterus for embryo implantation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GnRH agonist (Diphereline) and letrozole (Femara) followed by estradiol valerate and progesterone
What this could lead to: If successful, this could identify a better way to prepare the uterus for embryo transfer in women with adenomyosis, potentially increasing the chance of a live birth.
What could go wrong: This is a relatively small, early-phase trial (222 participants) comparing two existing protocols, so results may not be definitive or widely applicable. Side effects from the hormone treatments, such as headaches or mood changes, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOMYOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenomyosis ventricular fibrillation, paroxysmal familial, type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOMYOSIS FROZEN EMBRYO TRANSFER IVF

Contacts and locations

Locations

My Duc Hospital
RECRUITING

Ho Chi Minh City, Ho Chi Minh City, 70000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.